YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00899093 |
Recruitment Status
:
Active, not recruiting
First Posted
: May 12, 2009
Last Update Posted
: May 4, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Fallopian Tube Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Malignant Ovarian Brenner Tumor Malignant Ovarian Clear Cell Tumor Malignant Ovarian Endometrioid Tumor Malignant Ovarian Mixed Epithelial Tumor Malignant Ovarian Mucinous Tumor Malignant Ovarian Neoplasm Malignant Ovarian Serous Tumor Malignant Ovarian Transitional Cell Tumor Ovarian Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Stage IIIA Fallopian Tube Cancer Stage IIIA Ovarian Cancer Stage IIIA Primary Peritoneal Cancer Stage IIIB Fallopian Tube Cancer Stage IIIB Ovarian Cancer Stage IIIB Primary Peritoneal Cancer Stage IIIC Fallopian Tube Cancer Stage IIIC Ovarian Cancer Stage IIIC Primary Peritoneal Cancer Stage IV Fallopian Tube Cancer Stage IV Ovarian Cancer Stage IV Primary Peritoneal Cancer Undifferentiated Fallopian Tube Carcinoma Undifferentiated Ovarian Carcinoma | Other: Cytology Specimen Collection Procedure Other: Laboratory Biomarker Analysis |
PRIMARY OBJECTIVES:
I. To assess the ability of the YKL-40 serum marker to detect response or lack of response to primary chemotherapy in International Federation of Gynecology and Obstetrics (FIGO) stage III or IV invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer.
II. To compare the predictive accuracy of YKL-40 with cancer antigen 125 (CA125).
SECONDARY OBJECTIVES:
I. To test the ability of the YKL-40 serum marker to detect recurrence of ovarian, primary peritoneal, or fallopian tube cancer in patients who are in first remission following primary chemotherapy.
II. To test the ability of the YKL-40 serum marker to predict poor risk patients with FIGO stage III or IV invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer.
TERTIARY OBJECTIVES:
I. To explore alternative cut-off values for YKL-40 elevation in this large patient population.
II. To describe the variability of YKL-40 and CA125 measurements in patients receiving primary chemotherapy and in primary remission in a large patient population.
III. To describe the accuracy of YKL-40 coupled with CA125 measurements in predicting chemotherapy response, progression-free survival and overall survival.
OUTLINE:
Patients undergo collection of serum samples for analysis of YKL-40 via enzyme-linked immunosorbent assay (ELISA) and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
Study Type : | Observational |
Estimated Enrollment : | 2500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy |
Study Start Date : | September 2007 |
Estimated Primary Completion Date : | January 2100 |

Group/Cohort | Intervention/treatment |
---|---|
Ancillary-Correlative (serum collection for YKL-40 and CA125)
Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
|
Other: Cytology Specimen Collection Procedure
Correlative studies
Other Name: Cytologic Sampling
Other: Laboratory Biomarker Analysis
Correlative studies
|
- CA125 measurements [ Time Frame: Up to 10 years ]The accuracy of each marker alone will be compared using area under the ROC curve, and assess which adds more predictive information when both are included in logistic regression.
- Objective response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria [ Time Frame: Up to 10 years ]In order to make a valid comparison between CA125 and YKL-40, in this study computed tomography (CT) criteria will be treated as the "gold standard" and whether changes in YKL-40 levels correlate with CT evidence as well as or better than changes in CA125 levels will be evaluated.
- Time to disease progression using RECIST criteria [ Time Frame: Up to 10 years ]Parallel statistical analyses of time to disease progression will also be conducted for patients who do not respond.
- Time to tumor recurrence (relapse) [ Time Frame: From study entry until disease recurrence, death or date of last contact, assessed up to 10 years ]Parallel analyses of the markers as predictors of time-to-relapse will be performed using survival-type regression methods such as the Cox proportional hazards model or a parametric maximum likelihood model. The total number of patients available for analysis of time to relapse is the number of patients who respond to treatment.
- YKL-40 measurements [ Time Frame: Up to 10 years ]YKL-40 will be compared to CA125 in terms of its ability to detect response to chemotherapy (during chemotherapy) and recurrence of disease (in remission). Serum YKL-40 behavior will also be assessed as a reflection of tumor histology, tumor grade, and tumor stage—all in comparison to CA125. The accuracy of each marker alone will be compared using area under the receiver operating characteristic (ROC) curve, and assess which adds more predictive information when both are included in logistic regression.
- Chemotherapy response [ Time Frame: Up to 10 years ]As an exploratory analysis, the accuracy of YKL-40 coupled with CA125 measurements in predicting chemotherapy response will be described.
- Optimal cut-off values for YKL-40 [ Time Frame: Up to 10 years ]Optimal cut-off values for YKL-40 that subsequently can be used in clinical practice will be determined. Any statistical significance calculated for an optimized cut-off will adjust for the selection process, and any comparison with CA-125 will treat both markers in the same way.
- Overall survival [ Time Frame: From entry into the study to death or the date of last contact, assessed up to 10 years ]As an exploratory analysis, the accuracy of YKL-40 coupled with CA125 measurements in predicting overall survival will be described.
- Progression-free survival [ Time Frame: From study entry until disease progression, death or date of last contact, assessed up to 10 years ]As an exploratory analysis, the accuracy of YKL-40 coupled with CA125 measurements in predicting progression-free survival will be described.
- Variability of CA125 measurements [ Time Frame: Up to 10 years ]Linear statistical methods, such as a random effects model, will be used to assess the variability and correlation of CA125 over time in this population.
- Variability of YKL-40 measurements [ Time Frame: Up to 10 years ]Linear statistical methods, such as a random effects model, will be used to assess the variability and correlation of YKL-40 over time in this population.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients with a histologic diagnosis of FIGO stage III or IV invasive epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who will receive primary chemotherapy for newly diagnosed disease; eligible histologic cell types include serous, mucinous, endometrioid, clear cell, transitional, mixed epithelial, undifferentiated, adenocarcinoma, not otherwise specified (NOS) and malignant Brenner tumor
- Patients who have undergone full surgical staging as described in the Gynecologic Oncology Group (GOG) Surgical Procedures Manual
- Patients who have met the pre-entry requirements
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
Exclusion Criteria:
- The following histologic cell types are not eligible: carcinosarcoma (malignant mixed Mullerian tumor) and borderline epithelial tumors (low malignant potential, atypical proliferative)
- Patients with a current diagnosis of borderline epithelial ovarian tumor (formerly "tumors of low malignant potential") or recurrent invasive epithelial ovarian cancer treated with surgery only (such as those with stage IA or IB low grade lesions) are not eligible; patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor
- Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
- Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than IB; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO grade 3 lesions
- With the exception of non-melanoma skin cancer and other specific malignancies as noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this protocol therapy are excluded
- Patients who receive neoadjuvant chemotherapy prior to surgical staging
- Individuals with a diagnosis of rheumatoid arthritis, severe uncontrolled osteoarthritis, hepatic fibrosis or other active chronic inflammatory condition

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899093

United States, Alabama | |
University of South Alabama Mitchell Cancer Institute | |
Mobile, Alabama, United States, 36688 | |
United States, Arizona | |
Saint Joseph's Hospital and Medical Center | |
Phoenix, Arizona, United States, 85013 | |
United States, Arkansas | |
Highlands Oncology Group PA - Fayetteville | |
Fayetteville, Arkansas, United States, 72703 | |
United States, California | |
Providence Saint Joseph Medical Center/Disney Family Cancer Center | |
Burbank, California, United States, 91505 | |
UC Irvine Health/Chao Family Comprehensive Cancer Center | |
Orange, California, United States, 92868 | |
United States, Connecticut | |
Hartford Hospital | |
Hartford, Connecticut, United States, 06102 | |
Smilow Cancer Hospital Care Center at Saint Francis | |
Hartford, Connecticut, United States, 06105 | |
The Hospital of Central Connecticut | |
New Britain, Connecticut, United States, 06050 | |
United States, Delaware | |
Beebe Medical Center | |
Lewes, Delaware, United States, 19958 | |
Christiana Care Health System-Christiana Hospital | |
Newark, Delaware, United States, 19718 | |
United States, Florida | |
UF Cancer Center at Orlando Health | |
Orlando, Florida, United States, 32806 | |
United States, Georgia | |
Northside Hospital | |
Atlanta, Georgia, United States, 30342 | |
Central Georgia Gynecologic Oncology | |
Macon, Georgia, United States, 31201 | |
United States, Idaho | |
Saint Alphonsus Cancer Care Center-Boise | |
Boise, Idaho, United States, 83706 | |
United States, Illinois | |
Saint Anthony's Health | |
Alton, Illinois, United States, 62002 | |
Sudarshan K Sharma MD Limted-Gynecologic Oncology | |
Hinsdale, Illinois, United States, 60521 | |
Good Samaritan Regional Health Center | |
Mount Vernon, Illinois, United States, 62864 | |
Carle Cancer Center | |
Urbana, Illinois, United States, 61801 | |
Northwestern Medicine Cancer Center Warrenville | |
Warrenville, Illinois, United States, 60555 | |
United States, Indiana | |
Indiana University/Melvin and Bren Simon Cancer Center | |
Indianapolis, Indiana, United States, 46202 | |
Franciscan Health Indianapolis | |
Indianapolis, Indiana, United States, 46237 | |
Saint Vincent Hospital and Health Care Center | |
Indianapolis, Indiana, United States, 46260 | |
United States, Iowa | |
Iowa Methodist Medical Center | |
Des Moines, Iowa, United States, 50309 | |
Iowa-Wide Oncology Research Coalition NCORP | |
Des Moines, Iowa, United States, 50309 | |
Medical Oncology and Hematology Associates-Des Moines | |
Des Moines, Iowa, United States, 50309 | |
Medical Oncology and Hematology Associates-Laurel | |
Des Moines, Iowa, United States, 50314 | |
Mercy Medical Center - Des Moines | |
Des Moines, Iowa, United States, 50314 | |
Iowa Lutheran Hospital | |
Des Moines, Iowa, United States, 50316 | |
University of Iowa/Holden Comprehensive Cancer Center | |
Iowa City, Iowa, United States, 52242 | |
United States, Kansas | |
Providence Medical Center | |
Kansas City, Kansas, United States, 66112 | |
United States, Kentucky | |
Saint Elizabeth Medical Center South | |
Edgewood, Kentucky, United States, 41017 | |
Baptist Health Lexington | |
Lexington, Kentucky, United States, 40503 | |
United States, Louisiana | |
Woman's Hospital | |
Baton Rouge, Louisiana, United States, 70817 | |
United States, Maine | |
Maine Medical Center-Bramhall Campus | |
Portland, Maine, United States, 04102 | |
United States, Maryland | |
Union Hospital of Cecil County | |
Elkton, Maryland, United States, 21921 | |
United States, Massachusetts | |
Baystate Medical Center | |
Springfield, Massachusetts, United States, 01199 | |
University of Massachusetts Memorial Health Care | |
Worcester, Massachusetts, United States, 01605 | |
United States, Michigan | |
Saint Joseph Mercy Hospital | |
Ann Arbor, Michigan, United States, 48106-0995 | |
Michigan Cancer Research Consortium NCORP | |
Ann Arbor, Michigan, United States, 48106 | |
Beaumont Hospital-Dearborn | |
Dearborn, Michigan, United States, 48124 | |
Saint John Hospital and Medical Center | |
Detroit, Michigan, United States, 48236 | |
Hurley Medical Center | |
Flint, Michigan, United States, 48502 | |
Genesys Regional Medical Center | |
Grand Blanc, Michigan, United States, 48439 | |
Cancer Research Consortium of West Michigan NCORP | |
Grand Rapids, Michigan, United States, 49503 | |
Spectrum Health at Butterworth Campus | |
Grand Rapids, Michigan, United States, 49503 | |
Allegiance Health | |
Jackson, Michigan, United States, 49201 | |
Borgess Medical Center | |
Kalamazoo, Michigan, United States, 49001 | |
Bronson Methodist Hospital | |
Kalamazoo, Michigan, United States, 49007 | |
West Michigan Cancer Center | |
Kalamazoo, Michigan, United States, 49007 | |
Sparrow Hospital | |
Lansing, Michigan, United States, 48912 | |
Saint Mary Mercy Hospital | |
Livonia, Michigan, United States, 48154 | |
Mercy Health Partners-Hackley Campus | |
Muskegon, Michigan, United States, 49442 | |
Saint Joseph Mercy Oakland | |
Pontiac, Michigan, United States, 48341 | |
Lake Huron Medical Center | |
Port Huron, Michigan, United States, 48060 | |
Saint Mary's of Michigan | |
Saginaw, Michigan, United States, 48601 | |
Saint John Macomb-Oakland Hospital | |
Warren, Michigan, United States, 48093 | |
United States, Mississippi | |
University of Mississippi Medical Center | |
Jackson, Mississippi, United States, 39216 | |
United States, Missouri | |
Saint Francis Medical Center | |
Cape Girardeau, Missouri, United States, 63703 | |
Saint Luke's Hospital of Kansas City | |
Kansas City, Missouri, United States, 64111 | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63110 | |
Mercy Hospital Saint Louis | |
Saint Louis, Missouri, United States, 63141 | |
Saint Louis-Cape Girardeau CCOP | |
Saint Louis, Missouri, United States, 63141 | |
Cancer Research for the Ozarks NCORP | |
Springfield, Missouri, United States, 65804 | |
Mercy Hospital Springfield | |
Springfield, Missouri, United States, 65804 | |
CoxHealth South Hospital | |
Springfield, Missouri, United States, 65807 | |
United States, Montana | |
Billings Clinic Cancer Center | |
Billings, Montana, United States, 59101 | |
United States, Nebraska | |
Nebraska Methodist Hospital | |
Omaha, Nebraska, United States, 68114 | |
United States, Nevada | |
Women's Cancer Center of Nevada | |
Las Vegas, Nevada, United States, 89169 | |
United States, New Hampshire | |
Dartmouth Hitchcock Medical Center | |
Lebanon, New Hampshire, United States, 03756 | |
United States, New Jersey | |
Rutgers Cancer Institute of New Jersey | |
New Brunswick, New Jersey, United States, 08903 | |
United States, New York | |
Island Gynecologic Oncology | |
Brightwaters, New York, United States, 11718 | |
New York Hospital Medical Center of Queens | |
Fresh Meadows, New York, United States, 11365 | |
Winthrop University Hospital | |
Mineola, New York, United States, 11501 | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10065 | |
Stony Brook University Medical Center | |
Stony Brook, New York, United States, 11794 | |
State University of New York Upstate Medical University | |
Syracuse, New York, United States, 13210 | |
United States, North Carolina | |
Novant Health Presbyterian Medical Center | |
Charlotte, North Carolina, United States, 28204 | |
Rutherford Hospital | |
Rutherfordton, North Carolina, United States, 28139 | |
New Hanover Regional Medical Center/Zimmer Cancer Center | |
Wilmington, North Carolina, United States, 28401 | |
Southeast Clinical Oncology Research (SCOR) Consortium NCORP | |
Winston-Salem, North Carolina, United States, 27104 | |
Wake Forest University Health Sciences | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Ohio | |
Summa Akron City Hospital/Cooper Cancer Center | |
Akron, Ohio, United States, 44304 | |
Akron General Medical Center | |
Akron, Ohio, United States, 44307 | |
Aultman Health Foundation | |
Canton, Ohio, United States, 44710 | |
Good Samaritan Hospital - Cincinnati | |
Cincinnati, Ohio, United States, 45220 | |
MetroHealth Medical Center | |
Cleveland, Ohio, United States, 44109 | |
Ohio State University Comprehensive Cancer Center | |
Columbus, Ohio, United States, 43210 | |
Riverside Methodist Hospital | |
Columbus, Ohio, United States, 43214 | |
Miami Valley Hospital | |
Dayton, Ohio, United States, 45409 | |
United States, Oklahoma | |
University of Oklahoma Health Sciences Center | |
Oklahoma City, Oklahoma, United States, 73104 | |
Oklahoma Cancer Specialists and Research Institute-Tulsa | |
Tulsa, Oklahoma, United States, 74146 | |
United States, Pennsylvania | |
Abington Memorial Hospital | |
Abington, Pennsylvania, United States, 19001 | |
Bryn Mawr Hospital | |
Bryn Mawr, Pennsylvania, United States, 19010 | |
Paoli Memorial Hospital | |
Paoli, Pennsylvania, United States, 19301 | |
Thomas Jefferson University Hospital | |
Philadelphia, Pennsylvania, United States, 19107 | |
Reading Hospital | |
West Reading, Pennsylvania, United States, 19611 | |
Lankenau Medical Center | |
Wynnewood, Pennsylvania, United States, 19096 | |
Main Line Health NCORP | |
Wynnewood, Pennsylvania, United States, 19096 | |
United States, Rhode Island | |
Women and Infants Hospital | |
Providence, Rhode Island, United States, 02905 | |
United States, South Carolina | |
AnMed Health Cancer Center | |
Anderson, South Carolina, United States, 29621 | |
Saint Francis Hospital | |
Greenville, South Carolina, United States, 29601 | |
Greenville Health System Cancer Institute-Faris | |
Greenville, South Carolina, United States, 29605 | |
Greenville Memorial Hospital | |
Greenville, South Carolina, United States, 29605 | |
Greenville Health System Cancer Institute-Eastside | |
Greenville, South Carolina, United States, 29615 | |
Gibbs Cancer Center-Pelham | |
Greer, South Carolina, United States, 29651 | |
Greenville Health System Cancer Institute-Seneca | |
Seneca, South Carolina, United States, 29672 | |
Spartanburg Medical Center | |
Spartanburg, South Carolina, United States, 29303 | |
Greenville Health System Cancer Institute-Spartanburg | |
Spartanburg, South Carolina, United States, 29307 | |
United States, South Dakota | |
Black Hills Obstetrics and Gynecology | |
Rapid City, South Dakota, United States, 57701 | |
United States, Tennessee | |
Knoxville Gynecologic Cancer Specialists PC | |
Knoxville, Tennessee, United States, 37920 | |
Vanderbilt University/Ingram Cancer Center | |
Nashville, Tennessee, United States, 37232 | |
United States, Texas | |
The Don and Sybil Harrington Cancer Center | |
Amarillo, Texas, United States, 79106 | |
Baylor All Saints Medical Center at Fort Worth | |
Fort Worth, Texas, United States, 76104 | |
United States, Virginia | |
Virginia Commonwealth University/Massey Cancer Center | |
Richmond, Virginia, United States, 23298 | |
United States, Wisconsin | |
Marshfield Clinic Cancer Center at Sacred Heart | |
Eau Claire, Wisconsin, United States, 54701 | |
Sacred Heart Hospital | |
Eau Claire, Wisconsin, United States, 54701 | |
Aurora BayCare Medical Center | |
Green Bay, Wisconsin, United States, 54311 | |
Marshfield Clinic | |
Marshfield, Wisconsin, United States, 54449 | |
Saint Joseph's Hospital | |
Marshfield, Wisconsin, United States, 54449 | |
Aurora Saint Luke's Medical Center | |
Milwaukee, Wisconsin, United States, 53215 | |
Froedtert and the Medical College of Wisconsin | |
Milwaukee, Wisconsin, United States, 53226 | |
Marshfield Clinic-Minocqua Center | |
Minocqua, Wisconsin, United States, 54548 | |
Marshfield Clinic at James Beck Cancer Center | |
Rhinelander, Wisconsin, United States, 54501 | |
Marshfield Clinic-Rice Lake Center | |
Rice Lake, Wisconsin, United States, 54868 | |
Marshfield Clinic Cancer Care at Saint Michael's Hospital | |
Stevens Point, Wisconsin, United States, 54481 | |
Saint Michael's Hospital | |
Stevens Point, Wisconsin, United States, 54481 | |
Marshfield Clinic-Wausau Center | |
Wausau, Wisconsin, United States, 54401 | |
Aurora West Allis Medical Center | |
West Allis, Wisconsin, United States, 53227 | |
Diagnostic and Treatment Center | |
Weston, Wisconsin, United States, 54476 | |
Marshfield Clinic - Weston Center | |
Weston, Wisconsin, United States, 54476 | |
Marshfield Clinic - Wisconsin Rapids Center | |
Wisconsin Rapids, Wisconsin, United States, 54494 |
Principal Investigator: | Katherine Bell-McGuinn | NRG Oncology |
Responsible Party: | Gynecologic Oncology Group |
ClinicalTrials.gov Identifier: | NCT00899093 History of Changes |
Other Study ID Numbers: |
GOG-0235 NCI-2009-01083 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) CDR0000540250 GOG-0235 ( Other Identifier: NRG Oncology ) GOG-0235 ( Other Identifier: CTEP ) U10CA180868 ( U.S. NIH Grant/Contract ) U10CA027469 ( U.S. NIH Grant/Contract ) |
First Posted: | May 12, 2009 Key Record Dates |
Last Update Posted: | May 4, 2017 |
Last Verified: | May 2017 |
Additional relevant MeSH terms:
Carcinoma Neoplasms Adenocarcinoma Ovarian Neoplasms Fallopian Tube Neoplasms Peritoneal Neoplasms Carcinoma, Transitional Cell Carcinoma, Endometrioid Cystadenocarcinoma, Serous Adenocarcinoma, Mucinous Cystadenocarcinoma Adenocarcinoma, Clear Cell Brenner Tumor Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Endocrine Gland Neoplasms Neoplasms by Site Ovarian Diseases Adnexal Diseases Genital Diseases, Female Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders Fallopian Tube Diseases Abdominal Neoplasms Digestive System Neoplasms Digestive System Diseases Peritoneal Diseases Endometrial Neoplasms |